Hamit Bologur

Hamit Bologur

Auto-generated profile, based on publicly available information

Hamit Bologur

Prof. Dr. Cemil Tascioglu City Hospital, University of Health Sciences, Department of Pediatric Allergy and Immunology, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2024 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
NCNilay Caliskan
Nilay Caliskan
GYGuler Yildirim
Guler Yildirim
HBHamit Bologur
Hamit Bologur
HGHilal Gungor
Hilal Gungor
MŞmerve karaca şahin
merve karaca şahin
DODeniz Ozceker
Deniz Ozceker

12 November 2024 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
NÇNilay Çalışkan
Nilay Çalışkan
ŞGŞeyma Genç
Şeyma Genç
GYGüler Yıldırım
Güler Yıldırım
HBHamit Bologur
Hamit Bologur
HGHilal Güngör
Hilal Güngör
DÖDeniz Özçeker
Deniz Özçeker
Background. Food allergy is a public health issue that has a significant impact on the lives of families. Parental self-efficacy/confidence is important in managing food allergies. The aim of this study is to validate the “Food Allergy Self-Efficacy Scale for Parents” (FASE-P) and assess parental self-efficacy in managing their child’s food allergy. Methods. Turkish version of the FASE-P (T-FASE-P) was administered to 347 parents of children aged 0-18 who had been followed for at least one month due to food allergy at the Pediatric Allergy Clinic of Prof. Dr. Cemil Taşcıoğlu City Hospital between September 1 and December 31, 2023, through face-to-face interviews and online surveys for parents of children with food allergies from the general population. Content validity, exploratory factor analysis (EFA), and confirmatory factor analysis (CFA) were conducted to evaluate the validity of the scale. General Self-Efficacy Scale (GSES) was used for concurrent criterion validity. Internal consistency analysis, test-retest application, and item analysis were conducted to assess its reliability. Results. T-FASE-P scale initially contained 21 items, and the Cronbach’s alpha coefficient (α) calculated in this form was found to be 0.89. Later, when 4 items were excluded, the 17-item version of the scale was calculated as α=0.90. The intra-class correlation coefficient between the test and re-test was found to be 0.972. The content validity index value of the scale was calculated as 0.99, indicating that the content validity was at a sufficient level. In the EFA, it was determined that the scale formed a three-factor structural model and that this model explained 60.82% of the total variance. As a result of the CFA, the fit indices were calculated as χ2/df=2.341, GFI=0.919, TLI=0.950, indicating a good level of fit. Based on the analysis results, T-FASE-P consists of 17 items and three subscales. Conclusion. T-FASE-P scale is a valid and reliable measurement tool that can be used to determine the food allergy self-efficacy of Turkish parents.

31 May 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
NÇNilay Çalışkan
Nilay Çalışkan
MŞmerve karaca şahin
merve karaca şahin
GYGüler Yıldırım
Güler Yıldırım
ATAslı Berivan Topçak
Aslı Berivan Topçak
SKSefika Ilknur Kökcü Karadag
Sefika Ilknur Kökcü Karadag
DODeniz Ozceker
Deniz Ozceker
Background: Food allergy management requires dietary adherence, prevention of accidental exposures, and prompt reaction management. Identifying sociodemographic factors linked to low self‐efficacy may improve management. Methods: This study was conducted among parents of children diagnosed with food allergy who presented to our clinic. Participants completed the Turkish version of the Food Allergy Self‐Efficacy Scale for Parents (T‐FASE‐P, previously validated as EBA‐ÖZ) and the General Self‐Efficacy Scale (GSES). Results: A total of 280 parents (mothers, 85.4%; fathers, 14.6%) were included in the study. Of the children, 64.6% were boys and 35.4% were girls. The median parental age was 33 years (20–59), and the median child age was 25.5 months (3–213). Parents of children with egg and cow's milk allergy had lower T‐FASE‐P scores, while carrying an epinephrine auto‐injector and baked egg tolerance were associated with higher scores ( p < .05). Lowest scores related to school safety, cross‐contamination, and travel. In multivariable analyses, only school attendance ( p = .004) and cow's milk allergy ( p = .002) remained significant. Subscale analyses showed that school attendance was associated with prevention and recognition/management ( p = .002), parental employment with social activities ( p < .001), and IgE‐mediated allergy with recognition/management ( p = .027), whereas cow's milk allergy was consistently associated with lower scores across all subscales ( p < .05). Conclusion: This study evaluated parental self‐efficacy in relation to demographics. Cow's milk allergy was associated with lower, and carrying an adrenaline auto‐injector with higher self‐efficacy. These findings emphasize the need for targeted support for families managing high‐risk allergens.

7 January 2026 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
ŞKŞefika İlknur Kökcü Karadağ
Şefika İlknur Kökcü Karadağ
ATAslı Berivan Topçak
Aslı Berivan Topçak
BEBiray Ertürk
Biray Ertürk
NÇNilay Çalışkan
Nilay Çalışkan
HBHamit Bologur
Hamit Bologur
DÖDeniz Özçeker
Deniz Özçeker

8 September 2026 in Acta Paediatrica
Verified
Journal Article
Open access
PDF file
GNGüler Yıldırım Nalbant
Güler Yıldırım Nalbant
RCRaif Coşkun
Raif Coşkun
NÇNilay Çalışkan
Nilay Çalışkan
MŞmerve karaca şahin
merve karaca şahin
ATAslı Berivan Topçak
Aslı Berivan Topçak
DÖDeniz Özçeker
Deniz Özçeker
Aim: This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods: The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated. Results: In adults, higher baseline Systemic Inflammation Response Index (SIRI) (OR = 0.207, p < 0.001), monocyte count (OR = 0.276, p = 0.002), neutrophil‐to‐lymphocyte ratio (NLR) (OR = 0.455, p = 0.012), and Systemic Immune‐Inflammation Index (SII) (OR = 0.487, p = 0.022) were associated with lower odds of treatment response. In paediatric patients, higher baseline SII was significantly associated with lower odds of response (OR = 0.349, p = 0.040). Interaction analyses showed nominally significant age interactions for baseline SIRI (B = −0.169, p = 0.027) and monocyte count (B = −0.193, p = 0.025). During follow‐up, SIRI was lower in responders from baseline through 12 months in adults, and at 3 and 6 months in children. SII was lower in responders at baseline in adults, and at baseline, 3, and 6 months in children (all p < 0.05). Conclusion: Our findings suggest potential differences in the associations between inflammatory markers and omalizumab response across age groups, though further studies are needed to clarify age‐related differences.

21 October 2026 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ÇTÇağla Öztürk Turan
Çağla Öztürk Turan
NÇNilay Çalışkan
Nilay Çalışkan
ATAslı Berivan Topçak
Aslı Berivan Topçak
GYGüler Yıldırım
Güler Yıldırım
MŞmerve karaca şahin
merve karaca şahin
DODeniz Ozceker
Deniz Ozceker